Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Airway Resistance Reduction via Low-Density Gas Flow describes a therapeutic approach rather than a specific molecular target. It involves the substitution of nitrogen with helium to reduce gas density and Reynolds number, promoting laminar flow and reducing turbulent flow-related resistance in large airways.
Substitution of nitrogen with helium reduces gas density and Reynolds number, promoting laminar flow and reducing turbulent flow-related resistance in large airways. In small airways where flow is already laminar and independent of density, this effect is minimal. The main benefit occurs in large airways where turbulent flow predominates. The Hagen–Poiseuille equation governs laminar flow resistance; under these conditions, only viscosity matters. For turbulent or transitional flows in larger airways, reduced density decreases resistance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Airway Resistance Reduction via Low-Density Gas Flow.